Dan Schell articles

51. Are You Ready For A “Right Fight?” 3/9/2010

    I’m intrigued by companies that stay committed to their management strategies even during tough economic times. After all, there’s always someone breathing down a manager’s, president’s, or CEO’s neck when times are darkest and yammering about the need for widespread change or some kind of an “overhaul.”

52. Can Your Cold Chain Hurt Your Company's Brand? 3/8/2010

    Consider how important it is for the physicians administering your drugs to have a good perception about your company. And by good perception, I don’t mean that they just are satisfied with the drugs you produce, I mean they like the drugs and your company in general; they feel confident that you’re top-notch. Sure, there is a lot of marketing that goes into creating that perception, but what you may not realize is that your cold chain processes and technologies can have just as big an impact on a customer’s perception as any advertising or marketing campaign. 

53. Double-Digit Growth: The Next Step For Dr. Reddy's 3/7/2010

    It’s 6:30 p.m. in Hyderabad, India, and G.V. Prasad is not where I expected him to be. The vice chairman and CEO of the $1.2B Dr. Reddy’s Laboratories, the second-largest pharmaceutical company in India, is not in his office surrounded by lawyers and PR staffers poised to interject during our interview with their spin on a particular topic. 

54. Generics, Biologics, And Other Industrywide Trends 2/9/2010

    As we enter only the second month of 2010, many pharmaceutical executives are already looking ahead to — and many are likely dreading — 2011. That’s when some of the most profitable blockbuster drugs (e.g. Lipitor, Plavix, Seroquel, Zyprexa) will come off patent. Of course, dealing with drug patent expirations and the resulting increase of generics in the marketplace is nothing new to pharma executives.

55. Editorial Catalysts 2/1/2010

    I’m not going to lie to you — some of the articles in this issue may make you … well, nervous. But that may be a good thing. Let me explain.

56. A Q&A With Brik Eyre, GM Of Baxter Healthcare BioPharma Solutions 1/22/2010

    Brik Eyre: The CMO industry has become increasingly competitive. There continues to be overcapacity in the market. We are seeing an increase in globalization, customer service philosophies such as on-time delivery commitments, expansion of service offerings (i.e. additional regulatory, development, and packaging services), and product innovation as a way for the industry to remain competitive.

57. Editor's Note 1/1/2010

    In November 2009 I received an email from a reader asking why we hadn’t featured any minorities or women on our covers (we had published eight issues at this point). Ironically, at the time we were working on the two female-focused articles in this issue...

58. Q&A Regarding The Use Of Electronic Document Mgt. Systems (EDMSs) In Pharma 12/1/2009

    While the ideal goal is paperless, the practical reality is that paper will exist for a long period of time. The paperless goal is primarily focused in the traditional high-revenue markets of the United States, the European Union, and Japan; however, this is changing as emerging markets (Brazil, Russia, India, and China) are growing in revenue and clinical trial importance. Extending paperless programs into these regions and other emerging market countries is complex and time-consuming.

59. Social Media Goes To Washington, D.C. 12/1/2009

    On Nov. 12-13, I watched select portions of the live feed from the public hearing titled “Promotion of FDA-Regulated Medical Products Using the Internet and Social Media” in Washington, D.C. Speakers presented almost every 15 minutes and included a wide variety of people, including some from large pharma companies, Google, Yahoo!, PhRMA, and consumer/patient groups.

60. Tips For Enterprisewide ERP Deployment In Pharma 11/13/2009

    This month Life Science Leader investigates the topic of ERP (enterprise resource planning). To do so, we gathered input from two companies that have recently implemented ERP systems — Cayman Chemical, which manufactures biochemicals, and Synalloy Corp., which produces specialty chemicals for the pharma industry.